Evaluation of Atuna Racemosa Toxicity
Completed · Phase 1
Conditions studied: Bacterial Infections
In brief
For thousands of years people in the South Pacific have used Atuna racemosa extract as a topical anti-inflammatory. We, the researchers at the Mayo Clinic, have shown this extract to also have antibacterial properties. While this extract has been used for decades in the South Pacific, a controlled clinical trial to evaluate toxicity has never been performed.
Key facts
- Study ID
- NCT00318344
- Run by
- Mayo Clinic
- People needed
- 20
- Starts
- 2006-04-01
- Expected to finish
- 2007-11-01
- Last updated by the study team
- 2010-02-02
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: accepted.
Where it is running
- Mayo Clinic — Rochester, Minnesota, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.